Nothing Special   »   [go: up one dir, main page]

EA201492237A1 - Индолкарбонитрилы в качестве модуляторов рецептора андрогенов - Google Patents

Индолкарбонитрилы в качестве модуляторов рецептора андрогенов

Info

Publication number
EA201492237A1
EA201492237A1 EA201492237A EA201492237A EA201492237A1 EA 201492237 A1 EA201492237 A1 EA 201492237A1 EA 201492237 A EA201492237 A EA 201492237A EA 201492237 A EA201492237 A EA 201492237A EA 201492237 A1 EA201492237 A1 EA 201492237A1
Authority
EA
Eurasian Patent Office
Prior art keywords
modulators
androgen receptor
indolcarbonitriles
compounds
producing
Prior art date
Application number
EA201492237A
Other languages
English (en)
Other versions
EA026371B8 (ru
EA026371B1 (ru
Inventor
Филип Стюарт Тёрнбулл
Родольфо Кадилла
Original Assignee
ГЛАКСОСМИТКЛАЙН ИНТЕЛЛЕКЧУАЛ (No.2) ДИВЕЛОПМЕНТ ПРОПЕРТИ ЛИМИТЕД
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49117887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201492237(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ГЛАКСОСМИТКЛАЙН ИНТЕЛЛЕКЧУАЛ (No.2) ДИВЕЛОПМЕНТ ПРОПЕРТИ ЛИМИТЕД filed Critical ГЛАКСОСМИТКЛАЙН ИНТЕЛЛЕКЧУАЛ (No.2) ДИВЕЛОПМЕНТ ПРОПЕРТИ ЛИМИТЕД
Publication of EA201492237A1 publication Critical patent/EA201492237A1/ru
Publication of EA026371B1 publication Critical patent/EA026371B1/ru
Publication of EA026371B8 publication Critical patent/EA026371B8/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

Данное изобретение относится к нестероидным соединениям, которые являются модуляторами рецептора андрогенов, а также к способам получения и применения таких соединений.
EA201492237A 2012-07-17 2013-07-15 Индолкарбонитрилы в качестве модуляторов рецептора андрогенов EA026371B8 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261672455P 2012-07-17 2012-07-17
US201361748874P 2013-01-04 2013-01-04
PCT/IB2013/001530 WO2014013309A1 (en) 2012-07-17 2013-07-15 Indolecarbonitriles as selective androgen receptor modulators

Publications (3)

Publication Number Publication Date
EA201492237A1 true EA201492237A1 (ru) 2015-06-30
EA026371B1 EA026371B1 (ru) 2017-03-31
EA026371B8 EA026371B8 (ru) 2017-06-30

Family

ID=49117887

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201492237A EA026371B8 (ru) 2012-07-17 2013-07-15 Индолкарбонитрилы в качестве модуляторов рецептора андрогенов

Country Status (39)

Country Link
US (5) US8957104B2 (ru)
EP (1) EP2875013B1 (ru)
JP (1) JP6106746B2 (ru)
KR (1) KR102127939B1 (ru)
CN (1) CN104619693B (ru)
AR (1) AR091770A1 (ru)
AU (1) AU2013291721B2 (ru)
BR (1) BR112015000940B1 (ru)
CA (1) CA2879104C (ru)
CL (1) CL2015000119A1 (ru)
CO (1) CO7240378A2 (ru)
CR (1) CR20150008A (ru)
CY (1) CY1120064T1 (ru)
DK (1) DK2875013T3 (ru)
DO (1) DOP2015000004A (ru)
EA (1) EA026371B8 (ru)
ES (1) ES2657912T3 (ru)
HK (1) HK1208867A1 (ru)
HR (1) HRP20180061T1 (ru)
HU (1) HUE036238T2 (ru)
IL (1) IL236448A (ru)
IN (1) IN2014KN02993A (ru)
JO (1) JO3384B1 (ru)
LT (1) LT2875013T (ru)
ME (1) ME02996B (ru)
MX (1) MX349943B (ru)
MY (2) MY198512A (ru)
NZ (1) NZ703129A (ru)
PE (1) PE20150371A1 (ru)
PH (1) PH12015500104A1 (ru)
PL (1) PL2875013T3 (ru)
PT (1) PT2875013T (ru)
RS (1) RS56810B1 (ru)
SG (1) SG11201408493WA (ru)
SI (1) SI2875013T1 (ru)
TW (1) TWI574946B (ru)
UY (1) UY34911A (ru)
WO (1) WO2014013309A1 (ru)
ZA (1) ZA201500096B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155099B2 (en) 2009-09-21 2018-12-18 Cook Regentec Llc Method for infusing stem cells
JP6106746B2 (ja) 2012-07-17 2017-04-05 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 選択的アンドロゲン受容体調節剤としてのインドールカルボニトリル類
US9902694B2 (en) * 2014-01-21 2018-02-27 GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED Crystalline forms
WO2016061534A1 (en) * 2014-10-16 2016-04-21 Gtx, Inc. METHODS OF TREATING UROLOGICAL DISORDERS USING SARMs
CN105130872B (zh) * 2015-08-25 2018-01-30 江西师范大学 一种3位三氟甲基取代吲哚的制备方法
CN110437125B (zh) * 2019-09-06 2021-03-12 苏州旺山旺水生物医药有限公司 一种Tezacaftor中间体II的制备方法
WO2022204235A1 (en) * 2021-03-23 2022-09-29 Nido Biosciences, Inc. Bicyclic compounds as androgen receptor modulators
CN115010574B (zh) * 2022-06-06 2024-01-05 爱斯特（成都）生物制药股份有限公司 1-溴-2-氯-4-氟-2碘苯的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL342995A1 (en) 1998-02-25 2001-07-16 Genetics Inst Inhibitors of phospholipase enzymes
PT1087970E (pt) * 1998-06-19 2004-06-30 Pfizer Prod Inc Compostos pirrolo¬2,3-d|pirimidina
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
AU2003245880A1 (en) 2002-05-24 2003-12-12 Bayer Cropscience Ag Process for the preparation of thioalkylamine derivatives
CN1960973A (zh) * 2004-03-30 2007-05-09 惠氏公司 作为去甲肾上腺素(ne)与血清素(5－h t)活性和单胺重摄取的调控剂以治疗血管舒缩症状(vms)的1－(1h－吲哚－1－基)－3－(4－甲基哌嗪－1－基)－1－苯基丙烷－2－醇衍生物和相关化合物
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
JP4917018B2 (ja) 2004-05-03 2012-04-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドローゲン受容体モジュレーター（ｓａｒｍｓ）としての新規インドール化合物
WO2005111028A1 (en) 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
CN1980934B (zh) 2004-05-03 2011-10-26 詹森药业有限公司 作为选择性雄激素受体调节剂（sarms）的新的吲哚衍生物
ATE462692T1 (de) 2004-06-01 2010-04-15 Hoffmann La Roche 3-amino-1-arylpropyl-indole als monoamin- wiederaufnahmehemmer
BRPI0613876A2 (pt) * 2005-07-29 2011-02-15 Pfizer Prod Inc derivados de pirrolo [2,3-d] pirimidina; seus intermediários e sìntese
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
CN101426778A (zh) * 2006-03-15 2009-05-06 惠氏公司 作为组胺-3拮抗剂的n-经取代-氮杂环基胺
AU2007227681A1 (en) * 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
ES2452343T3 (es) 2006-09-29 2014-04-01 Glaxosmithkline Llc Compuestos de indol sustituidos
MX2011001904A (es) * 2008-08-20 2011-03-29 Pfizer Compuestos de pirrolo[2,3-d]pirimidina.
WO2010118287A1 (en) * 2009-04-10 2010-10-14 Radius Health, Inc. Selective androgen receptor modulators
IN2012DN02577A (ru) * 2009-10-15 2015-08-28 Pfizer
WO2011075334A1 (en) * 2009-12-18 2011-06-23 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
CN103415289B (zh) 2010-07-07 2017-04-12 得克萨斯州大学系统董事会 前神经原性化合物
KR20140009291A (ko) * 2011-01-20 2014-01-22 머크 샤프 앤드 돔 코포레이션 미네랄로코르티코이드 수용체 길항제
ES2682755T3 (es) * 2011-12-21 2018-09-21 Jiangsu Hengrui Medicine Co. Ltd. Derivado del anillo heteroarilo de seis miembros de pirrol, método de preparación del mismo y sus usos medicinales
JP6106746B2 (ja) 2012-07-17 2017-04-05 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 選択的アンドロゲン受容体調節剤としてのインドールカルボニトリル類
US9902694B2 (en) * 2014-01-21 2018-02-27 GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED Crystalline forms

Also Published As

Publication number Publication date
IL236448A (en) 2016-10-31
EP2875013A1 (en) 2015-05-27
CN104619693A (zh) 2015-05-13
MX2015000825A (es) 2015-07-17
SG11201408493WA (en) 2015-02-27
AU2013291721A1 (en) 2015-02-26
IN2014KN02993A (ru) 2015-05-08
EP2875013B1 (en) 2017-11-29
SI2875013T1 (en) 2018-03-30
PH12015500104B1 (en) 2015-03-02
US11299457B2 (en) 2022-04-12
US8957104B2 (en) 2015-02-17
RS56810B1 (sr) 2018-04-30
CO7240378A2 (es) 2015-04-17
KR20150032333A (ko) 2015-03-25
UY34911A (es) 2014-02-28
IL236448A0 (en) 2015-02-26
JP6106746B2 (ja) 2017-04-05
US10196353B2 (en) 2019-02-05
PT2875013T (pt) 2018-02-28
CY1120064T1 (el) 2018-12-12
BR112015000940A2 (pt) 2017-06-27
US20190127326A1 (en) 2019-05-02
US9533948B2 (en) 2017-01-03
MY173845A (en) 2020-02-24
AR091770A1 (es) 2015-02-25
PH12015500104A1 (en) 2015-03-02
HK1208867A1 (en) 2016-03-18
BR112015000940B1 (pt) 2022-05-17
HUE036238T2 (hu) 2018-06-28
ES2657912T3 (es) 2018-03-07
MX349943B (es) 2017-08-21
ZA201500096B (en) 2017-07-26
NZ703129A (en) 2017-06-30
TW201416349A (zh) 2014-05-01
AU2013291721B2 (en) 2016-02-25
PE20150371A1 (es) 2015-03-27
CA2879104A1 (en) 2014-01-23
CL2015000119A1 (es) 2015-04-24
US10710963B2 (en) 2020-07-14
KR102127939B1 (ko) 2020-06-29
PL2875013T3 (pl) 2018-06-29
HRP20180061T1 (hr) 2018-02-23
JO3384B1 (ar) 2019-03-13
ME02996B (me) 2018-10-20
US20140024694A1 (en) 2014-01-23
LT2875013T (lt) 2018-02-26
EA026371B8 (ru) 2017-06-30
CR20150008A (es) 2015-03-09
MY198512A (en) 2023-09-01
DOP2015000004A (es) 2015-03-15
CA2879104C (en) 2020-08-25
JP2015522603A (ja) 2015-08-06
US20200270210A1 (en) 2020-08-27
EA026371B1 (ru) 2017-03-31
US20170073309A1 (en) 2017-03-16
WO2014013309A1 (en) 2014-01-23
DK2875013T3 (en) 2018-01-22
US20150080449A1 (en) 2015-03-19
TWI574946B (zh) 2017-03-21
CN104619693B (zh) 2019-08-13

Similar Documents

Publication Publication Date Title
PH12018500718A1 (en) Compounds useful as modulators of trpm8
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201492237A1 (ru) Индолкарбонитрилы в качестве модуляторов рецептора андрогенов
EA201491996A1 (ru) Антагонисты st2l и способы их применения
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201492219A1 (ru) Соединения и композиции для модуляции egfr активности
EA201492002A1 (ru) Противовирусные соединения
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EA201890333A1 (ru) Противовирусные соединения
CO7151485A2 (es) Anticuerpos anti-sez6 y métodos de empleo
EA201590868A1 (ru) Противовирусные соединения
EA201491530A1 (ru) Модуляторы рецепторов эстрогенов и их применение
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
EA201591746A1 (ru) Способы и композиции для ингибирования бромодомен-содержащих белков
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
UA109931C2 (xx) Піримідинциклогексильні модулятори глюкокортикоїдних рецепторів
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201891397A1 (ru) Твердые фармацевтические композиции антагонистов рецепторов андрогенов
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
EA201491195A1 (ru) Способ получения композиции, содержащей галактоолигосахариды
EA201890434A1 (ru) Антитела к cd154 и способы их применения
EA201591380A1 (ru) АНТАГОНИСТЫ Kv1.3 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201370247A1 (ru) Гипертония и гиперурикемия
EA201691632A1 (ru) Пиразины в качестве модуляторов gpr6

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG TM